Caribou Biosciences, Inc. Common Stock CRBU

Caribou Biosciences, Inc. es una empresa biofarmacéutica de edición genómica en fase clínica. La empresa está desarrollando terapias transformadoras de repeticiones palindrómicas cortas regularmente interespaciadas (CRISPR) para pacientes con enfermedades devastadoras. La plataforma CRISPR de la empresa, CRISPR híbrido ARN-ADN (chRDNA), permite una precisión superior en la edición del genoma para desarrollar terapias celulares específicamente diseñadas para una mayor persistencia. Está avanzando en una cartera de terapias celulares allogénicas, o de venta libre, de receptor de antígeno quimérico (CAR)-T (CAR-T) y células CAR-natural killer (CAR-NK) para el tratamiento de pacientes con malignidades hematológicas y tumores sólidos. El candidato a producto principal de la empresa, CB-010, es una terapia celular allogénica anti-CD19 CAR-T en fase clínica con la proteína de muerte celular programada 1 (PD-1) eliminada de la superficie de la célula CAR-T mediante una eliminación editada genéticamente del gen PDCDI. El candidato a producto de la empresa también incluye CB-011, CB-012 y CB-020.

• Zacks Investment Research 31 ago

  Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

  An analysis of stocks with strong potential to deliver earnings surprises identifies five companies: Allstate (ALL), Wayfair (W), BILL Holdings (BILL), Twilio (TWLO), and Caribou Biosciences (CRBU). These stocks were selected based on positive earnings surprise history, strong Zacks Rank ratings, positive Earnings ESP, and solid long-term growth prospects. Historical data shows these companies have consistently beaten market expectations, with Allstate averaging a 45.34% earnings surprise over the past four quarters.

  

• GlobeNewswire Inc. 29 jun

  Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

  Caribou Biosciences announced positive clinical data for its CRISPR-based CAR-T cell therapies. Vispa-cel demonstrated an 82% overall response rate and 67% complete response rate in second-line large B cell lymphoma patients with a 17.1-month median progression-free survival. CB-011 showed an 83% complete response rate and 91% MRD negativity in heavily pretreated multiple myeloma patients, with 50% maintaining complete response at 15 months.

  

• GlobeNewswire Inc. 11 jun

  Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

  Caribou Biosciences reported positive clinical data for CB-011, its off-the-shelf BCMA-targeted CAR-T cell therapy for relapsed/refractory multiple myeloma. In 12 BCMA-naïve patients at the recommended dose, CB-011 achieved 83% complete response rate, 91% MRD negativity, and 50% of patients remained in complete response at 15 months with a manageable safety profile. The company also presented a case study of a patient previously treated with an approved CAR-T therapy who achieved complete response with CB-011. Dose expansion data is expected in H2 2026.